【 Warm congratulations 】 The phosphate oseltamivir capsules developed by Nanjing Daoqun Pharmaceutical R&D Co., Ltd. have been approved for market launch!

Daoqun Company recently received a Class 4 marketing authorization for oseltamivir phosphate capsules issued by the National Medical Products Administration (NMPA).

Early use of Aowei Shu ®， Flu worry free

Oseltamivir phosphate is an influenza virus neuraminidase inhibitor, an ethyl ester prodrug that requires ester hydrolysis to be converted into the active form of carboxylic acid Oseltamivir. Oseltamivir carboxylate is an inhibitor of influenza virus neuraminidase, which affects the release of virus particles. Oseltamivir phosphate is currently sold in over 60 countries and regions worldwide, and is recognized as one of the most effective drugs for preventing and treating influenza viruses. It can be used for the treatment of influenza A and B in adults and children aged 1 year and above (Oseltamivir phosphate can effectively treat influenza A and B, but clinical application data for influenza B is not yet available). Patients should use it within 48 hours of the first onset of symptoms. It can also be used for the prevention of influenza A and B in adults and adolescents aged 13 and above.

Basic information of drugs

The preferred medication for preventing and treating influenza, with a billion dollar market

Influenced by global public health events, the prevalence and superinfection of A, B and COVID-19 have greatly increased the market demand for oseltamivir. According to data from MineNet, it is predicted that the sales revenue of oseltamivir phosphate preparations in China will reach 10.2 billion yuan in 2023. Among them, the sales revenue of public hospitals in 2023H1 city is 2.13 billion yuan, and it is predicted that the terminal revenue of public hospitals for the whole year will be 6.89 billion yuan. The sales revenue of retail pharmacy terminals in 2023 is 3.35 billion yuan.

Phosphate oseltamivir capsules are the result of continuous research and development investment in the field of chemical drugs by Nanjing Daoqun Pharmaceutical. This approval will provide high-quality and affordable drugs for influenza patients, reduce their medication burden, and better meet the needs of the public and clinical treatment. At the same time, it enriches the company's product pipeline in the field of anti infection, expands market sales channels, strengthens the product supply chain, enhances the market competitiveness of the company's products, and has a positive impact on the company's future business performance.

- END -